Alten (ATE:TSX-V) Investor Relations Material

Overview

Antibe Therapeutics is a biotechnology company with a focus on developing innovative treatments for inflammation. The company aims to cater to the non-addictive management of chronic and post-surgical pain, offering significant potential for major markets. Leading the drug pipeline is a late-stage Phase 2 clinical trial that promises unparalleled safety in treating chronic pain, a condition that affects over 50 million Americans. Furthermore, the company aims to address the worldwide opioid crisis by developing a second pipeline drug to replace opioids in pain management. Finally, with a third daily aspirin, Antibe Therapeutics seeks to provide a safer option that delivers anti-stroke and anti-cancer benefits without harming the digestive tract.

Frequently Asked Questions

What is Alten's ticker?

Alten's ticker is ATE

What exchange is Alten traded on?

The company's shares trade on the TSX-V stock exchange

Where are Alten's headquarters?

They are based in Toronto, Ontario

How many employees does Alten have?

There are 11-50 employees working at Alten

What is Alten's website?

It is alten.com

What type of sector is Alten?

Alten is in the Healthcare sector

What type of industry is Alten?

Alten is in the Biotechnology industry

Who are Alten's peers and competitors?

The following five companies are Alten's industry peers:

- Faron

- ReNeuron

- Trillium Therapeutics Inc.

- OPKO Health

- Exopharm Limited